Moleculin Biotech Inc
NASDAQ:MBRX

Watchlist Manager
Moleculin Biotech Inc Logo
Moleculin Biotech Inc
NASDAQ:MBRX
Watchlist
Price: 7.24 USD -6.1%
Market Cap: 14.9m USD

Relative Value

There is not enough data to reliably calculate the relative value of MBRX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MBRX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-19.7
Industry
24
Forward
-0.3
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-20.5
Industry
21.6
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-20.5
Industry
23.7
vs History
vs Industry
46
Median 3Y
13
Median 5Y
16.3
Industry
3.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
24
Median 3Y
-8.1
Median 5Y
-17.5
Industry
6.7
Forward
-0.2
vs History
vs Industry
22
Median 3Y
-8.1
Median 5Y
-17.4
Industry
7.2
Forward
-0.3
vs History
vs Industry
26
Median 3Y
-9.3
Median 5Y
-19.2
Industry
8.2
vs History
vs Industry
22
Median 3Y
-9.3
Median 5Y
-19.2
Industry
6.7
vs History
96
vs Industry
67
Median 3Y
19.2
Median 5Y
46.8
Industry
5.7

Multiples Across Competitors

MBRX Competitors Multiples
Moleculin Biotech Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Moleculin Biotech Inc
NASDAQ:MBRX
14.9m USD 0 -0.4 -0.3 -0.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 071 784.8 -161 938.1 -196 644.6 -194 400.6
US
Abbvie Inc
NYSE:ABBV
398B USD 6.7 169.6 16.4 23.3
US
Amgen Inc
NASDAQ:AMGN
174.6B USD 4.9 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
151B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113B USD 9.6 30.8 22.5 23.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.7 -527.6 -574.5 -559.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.8B USD 5.2 16.3 15.5 17.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
57.1B USD 17.8 1 310.4 172.6 209.3
AU
CSL Ltd
ASX:CSL
89.8B AUD 3.8 19.9 13.3 16.6
NL
argenx SE
XBRU:ARGX
48B EUR 15.5 36.5 63.2 65
P/S Multiple
Revenue Growth P/S to Growth
US
Moleculin Biotech Inc
NASDAQ:MBRX
Average P/S: 3 407 392.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 071 784.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 067.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.2
6%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.8
46%
0.4
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.5
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Moleculin Biotech Inc
NASDAQ:MBRX
Average P/E: 203.4
Negative Multiple: -0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 938.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
169.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.8
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
9%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 310.4
N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
11%
1.8
NL
argenx SE
XBRU:ARGX
36.5
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Moleculin Biotech Inc
NASDAQ:MBRX
Average EV/EBITDA: 41.8
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 644.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.5
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
172.6
N/A N/A
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
NL
argenx SE
XBRU:ARGX
63.2
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Moleculin Biotech Inc
NASDAQ:MBRX
Average EV/EBIT: 48.2
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 400.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
13%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
209.3
N/A N/A
AU
CSL Ltd
ASX:CSL
16.6
11%
1.5
NL
argenx SE
XBRU:ARGX
65
N/A N/A